Research programme: WEE1 protein inhibitors - Almac Discovery

Drug Profile

Research programme: WEE1 protein inhibitors - Almac Discovery

Alternative Names: Debio 0123; Wee-1 inhibitor - Almac Discovery

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator Almac Discovery
  • Class Antineoplastics
  • Mechanism of Action WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Jun 2017 WEE-1 kinase inhibitor programme licensed to Debiopharm worldwide
  • 20 Jun 2017 Preclinical trials in Cancer in United Kingdom, before June 2017
  • 31 Dec 2013 Early research in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top